ASCO 2019: The eight biggest stories on anticancer agents
Here is ecancer’s speedy recap on the presentations from the 2019 American Society of Clinical…
Browsing: ASCO 2019
ASCO 2019: Debate-fuelling headlines you may have missed
With over 2400 abstracts presented at the 2019 American Society of Clinical Oncology (ASCO) Annual…
My Top 3 ASCO 2019 Abstracts by Prunella Blinman
Affordable Care Act (ACA) Medicaid expansion impact on racial disparities in time to cancer treatment…
Carboplatin & paclitaxel chemotherapy alone should remain standard treatment for endometrial cancer
The New England Journal of Medicine recently published the primary endpoint of the NRG Oncology clinical…
ASCO 2019: Cleveland researchers test novel gene therapy for glioblastoma
A novel gene therapy clinical trial at University Hospitals Seidman Cancer Center and the Case…
ASCO 2019: New TAILORx data guides adjuvant therapy in younger breast cancer patients
New information about adjuvant therapy to prevent recurrence of breast cancer in women 50 years…
ASCO 2019: No benefit from pazopanib in advanced kidney cancer after surgery to remove metastases
The E2810 research study was conducted to determine whether taking the oral drug pazopanib following…
ASCO 2019: NCI-MATCH trial finds the combination of dabrafenib and trametinib effective
Treatment with dabrafenib and trametinib, a drug combination designed to target cancers that harbour certain…
ASCO 2019: Suggested benefit in PCV chemoradiotherapy for both IDH-mutant WHO-defined molecular subgroups
A recent, updated predictive analysis of the three WHO-defined molecular subgroups based on isocitrate dehydrogenase…
ASCO 2019: New standard regimen for women with uterine carcinosarcomas
Results from the phase III NRG Oncology clinical trial GOG 0261 comparing paclitaxel plus carboplatin…